24/7 Market News Snapshot 21 May, 2025 – Polyrizon Ltd. Ordinary Shares (NASDAQ:PLRZ)

May 21, 2025

DENVER, Colo., 21 May, 2025 (www.247marketnews.com) – (Nasdaq:PLRZ) are discussed in this article.
Polyrizon Ltd. (Nasdaq:PLRZ), a pioneering biotech firm engaged in the development of innovative intranasal hydrogels, has exhibited significant bullish activity in the pre-market session, trading at $0.006, reflecting an increase of 17.88% from the previous close of $0.005. The notable trading volume of 111.82 million shares signals heightened investor interest and indicates potential momentum for the company. Technical analyses suggest that this upward trajectory may continue if buying pressure is sustained, with resistance levels noted around $0.007 and solid support observed at $0.005. Investors are advised to monitor market conditions closely, as the strong volume could indicate forthcoming volatility and opportunities for profit.

In a recent announcement, Polyrizon revealed promising results from its latest ex vivo studies, which demonstrated the exceptional mucoadhesive properties and extensive surface coverage of its proprietary formulation platform. Conducted in partnership with leading experts, these studies utilized excised rabbit nasal mucosa to model human nasal tissues and evaluate the effectiveness of the formulation’s capability to coat the nasal mucosa.

The research findings confirmed that Polyrizon’s advanced formulation spreads uniformly across the nasal surface, forming a consistent protective layer. State-of-the-art two-photon fluorescence microscopy was employed to ascertain the precise localization of the formulation amidst natural tissue autofluorescence, essential for enhancing localized protection and facilitating efficient delivery of therapeutic agents.

Furthermore, rigorous mucoadhesion tests revealed that the formulation maintains a robust bond to nasal tissue, even under simulated physiological conditions, ensuring prolonged retention essential for sustained therapeutic efficacy. Tomer Izraeli, CEO of Polyrizon, commented on the significance of these findings, emphasizing the formulation’s ability to provide localized protection and enhance drug delivery efficacy through its innovative Capture and Contain™ technology. As Polyrizon advances its proprietary solutions, it remains dedicated to improving intranasal delivery applications.

Related news for (PLRZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.